Biotie Therapies Oyj : David Cook appointed Chief Financial Officer of Biotie
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 2 January
2013 at 1:40 p.m
David Cook appointed Chief Financial Officer of Biotie
David Cook, (age 45), has been appointed Chief Financial Officer (CFO) of
Biotie Therapies Corp., effective February 25, 2013. He will become a member
of the Group's management team and will report to Timo Veromaa, President and
Chief Executive Officer. David will be based at the Company's headquarters in
Turku, Finland. Kristian Rantala, current interim CFO, will resume his prior
duties as Vice President, Finance and Administration, Finland.
David Cook, a British native, has extensive industry expertise in life science
enterprises in finance, strategy, investor relations and M&A. Previously David
was CFO, International, of Jazz Pharmaceuticals, Inc., a NASDAQ listed company
and before this CFO of EUSA Pharma Inc., which was acquired by Jazz
Pharmaceuticals in mid-2012. Before joining EUSA David was Group Financial
Controller at Zeneus Pharma Limited and prior to that worked for
PricewaterhouseCoopers in the United Kingdom and Australia. David is a
qualified chartered accountant and graduated from the University of Oxford
with a degree in Chemistry.
Timo Veromaa, CEO of Biotie:
"I am very pleased that David is joining Biotie's management team and we look
forward to his contributions to the growth of the group. As Biotie continues
to mature as a company, David's extensive experience in building profitable
biotech businesses will be extremely valuable."
Turku, 2 January 2013
Biotie Therapies Corp.
President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: email@example.com
NASDAQ OMX Helsinki Ltd
Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's
disease, Alzheimer's disease and other cognitive disorders, alcohol and drug
dependence (addiction) and post-traumatic stress disorder), and inflammatory
and fibrotic liver disease. The company has a strong and balanced development
portfolio with several innovative small molecule and biological drug
candidates at different stages of clinical development. Biotie's products
address diseases with high unmet medical need and significant market
Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck
A/S, has on 14 December 2012 received a positive opinion from the Committee
for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) recommending marketing authorization of Selincro(TM) for the reduction
of alcohol consumption in adult patients with alcohol dependence who have a
high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which has successfully
completed a Phase 2b study in 420 patients with advanced Parkinson's disease.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.